Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2023

Surveillance de l'innocuité du tofacitinib après sa mise sur le marché sur une période de 9 ans chez des patients atteints de rhumatisme psoriasique et de polyarthrite rhumatoïde

Rheumatol Ther. 2023;10(5):1255–1276 doi: 10.1007/s40744-023-00576-8

Nagy E,

Chen AS,

Kwok K,

Fallon L,

Kinch C

The data gathered in this post-marketing surveillance study aligned with the previously established safety profile of tofacitinib, and reports were found to have consistent safety profiles in the treatment of both patient with PsA and RA. However, the results of this study should be interpreted considering the limitations of post-marketing surveillance studies.

Keywords:

May 2019

Innocuité et efficacité du Tofacitinib allant jusqu'à 9,5 ans dans le traitement de la polyarthrite rhumatoïde: résultats finaux d'une étude de prolongation globale, ouverte et à long terme

Arthritis Res Ther. 2019 Apr 5;21(1):89.

Wollenhaupt J,

Lee EB,

Curtis JR,

Silverfield J,

Terry K,

Soma K,

Kwok K,

Wang L,

TOF 5 mg and 10mg BID demonstrated a consistent safety profile and sustained efficacy for up to 9.5 years in this open-label LTE ORAL Sequel study.TOF 5 mg and 10 mg BID demonstrated consistent safety (as monotherapy and combination therapy) and efficacy within this open-label LTE study of RA patients. As RA requires long-term treatment, it’s important to assess the long-term efficacy and safety of RA therapies to understand the potential lifelong impact on patient health and quality of life. Th...

Keywords:

December 2018

Évaluation des Effets à Court, Moyen et Long Terme du Tofacitinib sur les Lymphocytes Chez les Patients Atteints de Polyarthrite Rhumatoïde

Arthritis Rheumatol 2018 DOI: 10. 1002/art.40780

Lee EB,

Hazra A,

Hodge J,

Wang L,

Choy E

Tofacitinib (TOF) treatment is associated with short-term transient increases in absolute lymphocyte counts (ALC), followed by a gradual decline to reach steady state by ~48 months. Changes in both ALC and lymphocyte subset counts (LSC) were reversible upon TOF discontinuation. Low ALC but not LSC were associated with an increased risk of serious infective episodes (SIEs) and herpes zoster (HZ). This data supported the treatment recommendations on ALC counts for starting and continuing therapy w...